Q-omics provides the consensus-scored LEFTY1 profile across patient tissues and cancer cell-line models. LEFTY1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LEFTY1 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, LEFTY1 RNA expression shows 17,367 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where LEFTY1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LEFTY1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LEFTY1 survival associations across molecular data types. LEFTY1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LEFTY1 RNA expression–survival associations across cancer types. High LEFTY1 expression shows unfavorable associations in KIRP, ACC, MESO and LIHC, but favorable associations in SCLC and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LEFTY1 RNA expression.
This table summarizes LEFTY1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LEFTY1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LEFTY1 shows lower tumor expression in KICH, LUSC and PAAD and higher tumor expression in STAD, CHOL and UCEC. The KICH box plot shows higher LEFTY1 RNA expression in normal versus tumor tissue (log2 FC = −0.680, t-test p < 0.001).
This table shows molecular features associated with LEFTY1 in patient tissues and cancer cell lines. In patient samples, LEFTY1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LEFTY1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LUNG_SCLC.
